Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities

A deepening of understanding the molecular pathways of tumor progression have been the basic requirements for the development of so-called targeted therapies and ICIs. This new generation of drugs is designed to specifically block tumor cell proliferation, angiogenesis or immune escape mechanisms and intend to reduce high cytotoxicity associated with chemotherapy. On the one hand, much attention has been devoted to the notion that a growing tumor requires blood supply and allowed the development of monoclonal antibodies and small molecule inhibitors directed against angiopoietin-2 (Ang-2), vascular endothelial growth factor-A (VEGF-A), growth factor receptors or their downstream signaling [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research